Global Personalized Cell Therapy Market By Therapeutic Area (Neurological Disorders, Cardiovascular Diseases, Inflammatory Diseases, Diabetes, and Cancer), By Technology (Bone Marrow Transplantation, Platelet Transfusions, Packed Red Cell Transfusions, and Organ Transplantation), By End-users (Hospitals, Specialty Clinics, Homecare, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

Global Personalized Cell Therapy Market size is expected to be worth around US$ 127.1 billion by 2034 from US$ 14.2 billion in 2024, growing at a CAGR of 24.5% during the forecast period 2025 to 2034. In 2023, North America led the market, achieving over 41.2% share with a revenue of US$ 5.9 Billion.

Growing advancements in immunotherapy and regenerative medicine are driving the expansion of the personalized cell therapy market. Personalized cell therapies, such as CAR T-cell therapies, stem cell treatments, and gene-editing technologies, harness the power of an individual’s own cells to treat diseases like cancer, autoimmune disorders, and genetic conditions. The rising focus on precision medicine, which tailors treatment plans based on a patient’s unique genetic makeup, creates significant opportunities for the market.

In January 2024, Kite, a subsidiary of Gilead, obtained approval from the U.S. Food and Drug Administration for changes to the manufacturing process of its CAR T-cell therapy, Yescarta (axicabtagene ciloleucel). This adjustment will reduce the manufacturing time from 16 days to 14 days, enabling the earlier release and delivery of Yescarta, which will allow healthcare professionals to provide improved patient care.

Recent trends show an increasing emphasis on improving the scalability and cost-effectiveness of personalized cell therapies, allowing for broader accessibility. Innovations such as the integration of artificial intelligence in cell therapy development are enhancing treatment customization, improving outcomes, and reducing risks. As research progresses, the market will likely see continued expansion, with further breakthroughs in personalized treatments offering novel solutions to complex diseases.

Key Takeaways

• In 2023, the market for Personalized Cell Therapy generated a revenue of US$ 2 billion, with a CAGR of 24.5%, and is expected to reach US$ 127.1 billion by the year 2033.
• The therapeutic area segment is divided into neurological disorders, cardiovascular diseases, inflammatory diseases, diabetes, and cancer, with cardiovascular diseases taking the lead in 2023 with a market share of 48.7%.
• Considering technology, the market is divided into bone marrow transplantation, platelet transfusions, packed red cell transfusions, and organ transplantation. Among these, platelet transfusions held a significant share of 44.8%.
• Furthermore, concerning the end-users segment, the market is segregated into hospitals, specialty clinics, homecare, and others. The hospitals sector stands out as the dominant player, holding the largest revenue share of 58.2% in the Personalized Cell Therapy market.
• North America led the market by securing a market share of 41.2% in 2023.

By Therapeutic Area Analysis

The cardiovascular diseases segment led in 2023, claiming a market share of 48.7% owing to the increasing prevalence of heart disease and related conditions globally. Personalized cell therapies, such as stem cell-based treatments, are projected to offer promising solutions for repairing damaged heart tissue, improving blood vessel formation, and enhancing cardiac function. The rising number of cardiovascular diseases, driven by factors such as an aging population, unhealthy lifestyles, and hypertension, is likely to drive the demand for more effective, tailored therapies.

Personalized cell therapies are anticipated to improve outcomes in heart failure, myocardial infarction, and ischemic heart disease by providing regenerative treatment options. As advancements in cell-based therapies progress and demonstrate clinical success, the cardiovascular disease segment is expected to see sustained growth, especially with a growing focus on precision medicine and patient-specific treatment plans.

By Technology Analysis

The platelet transfusions held a significant share of 44.8% due to advancements in transfusion technologies and the increasing demand for personalized treatments. Platelet transfusions are likely to become more efficient with personalized cell therapy, offering targeted treatment for patients with conditions such as thrombocytopenia or those undergoing chemotherapy.

The development of cell-based platelet therapies, which use engineered cells to produce platelets or enhance platelet function, is expected to reduce the reliance on donated blood products and improve patient outcomes. The growing need for platelet transfusions in surgeries, trauma care, and cancer treatment is likely to drive demand for these personalized therapies. As hospitals and healthcare providers look for more effective and sustainable alternatives to traditional transfusions, the platelet transfusion segment is anticipated to experience significant growth, especially in areas with limited access to donor blood.

By End-users Analysis

The hospitals segment had a tremendous growth rate, with a revenue share of 58.2% owing to the increasing adoption of personalized medicine in clinical settings. Hospitals are likely to remain the primary end-users of cell therapies, especially for treating complex conditions such as cancer, cardiovascular diseases, and neurological disorders. The rise in the number of hospital-based clinical trials testing personalized cell therapies is projected to drive this growth.

Hospitals are anticipated to invest in advanced cell therapy technologies as they seek more targeted and effective treatment options for their patients. The growing prevalence of chronic diseases and the need for specialized, precision-based treatments are likely to further boost the demand for personalized cell therapies in hospitals. Additionally, the expansion of regenerative medicine treatments, which can offer personalized solutions for tissue repair and immune modulation, is expected to significantly contribute to the growth of the hospital segment in this market.

Key Market Segments

By Therapeutic Area

• Neurological Disorders
• Cardiovascular Diseases
• Inflammatory Diseases
• Diabetes
• Cancer

By Technology

• Bone Marrow Transplantation
• Platelet Transfusions
• Packed Red Cell Transfusions
• Organ Transplantation

By End-users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Drivers

Increasing Prevalence of Cancer Driving the Personalized Cell Therapy Market

Increasing prevalence of cancer is anticipated to drive the personalized cell therapy market significantly. In January 2024, the American Cancer Society projected that approximately 2.0 million new cancer cases would be diagnosed in the United States, up from an estimated 1.9 million in 2023. This rising cancer burden amplifies the demand for advanced and tailored treatment solutions. Personalized cell therapies, which utilize patient-specific cells for targeted interventions, are gaining prominence in oncology.

The ability of these therapies to address unique cancer profiles enhances treatment efficacy and minimizes adverse effects. Ongoing advancements in genetic engineering and immunotherapy strengthen the application of personalized approaches in cancer care. Pharmaceutical companies are investing in research to expand the therapeutic potential of cell-based treatments.

Growing adoption of precision medicine further aligns with the goals of personalized cell therapy in cancer management. Rising awareness among healthcare providers and patients supports the integration of these advanced treatments into standard care. Increasing funding from governments and private entities accelerates the development and commercialization of personalized therapies.

Collaborative efforts among biotech firms, academic institutions, and healthcare systems facilitate innovation and scalability. These trends position personalized cell therapy as a transformative solution for addressing the increasing cancer incidence globally.

Restraints

High Costs Are Restraining the Personalized Cell Therapy Market

High costs of developing and administering personalized cell therapy are restraining the market. Manufacturing personalized treatments involves complex processes, including cell harvesting, genetic modification, and quality control, which require specialized facilities and expertise. The time-intensive nature of producing patient-specific therapies adds to operational expenses, limiting accessibility for many patients.

In addition, the lack of scalable production methods poses challenges in meeting growing demand while maintaining affordability. Regulatory hurdles, including extensive clinical trials and approval requirements, increase the cost of bringing therapies to market. Limited insurance coverage for these innovative treatments further exacerbates affordability issues.

Smaller biotech companies often face financial constraints in conducting research and scaling production. Addressing these barriers requires advancements in manufacturing technologies, streamlined regulatory pathways, and supportive reimbursement policies to enhance accessibility and reduce costs.

Opportunities

Rising Number of Clinical Trials as an Opportunity for the Personalized Cell Therapy Market

Rising number of clinical trials is projected to create significant opportunities for the personalized cell therapy market. In October 2023, Aurion Biotech announced that the first patient in its phase 1/2 clinical trial of AURN001, an experimental therapy for corneal edema, had received treatment. This milestone underscores the growing focus on innovative therapies addressing unmet medical needs. Clinical trials for personalized cell therapies contribute to the development of advanced solutions for various diseases, including cancer and degenerative conditions.

Pharmaceutical companies increasingly invest in trials to validate the safety and efficacy of novel cell-based treatments. Expanding global participation in clinical trials accelerates the availability of cutting-edge therapies in multiple regions. Collaboration among research institutions and healthcare providers enhances trial success rates and facilitates data sharing. Technological advancements in cell engineering support the design of more effective and scalable therapies.

Increased patient enrollment in trials promotes robust data generation, critical for regulatory approvals. Government funding and public-private partnerships further encourage the initiation of clinical trials for innovative cell therapies. These trends highlight the critical role of clinical trials in driving innovation and expanding the potential of personalized cell therapy in modern healthcare.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors significantly influence the personalized cell therapy market. On the positive side, rising healthcare investments and advancements in biotechnology contribute to the increased adoption of cell-based therapies. The growing demand for personalized medicine, driven by the desire for tailored and effective treatments, accelerates market growth. However, economic downturns can result in reduced healthcare budgets and slower adoption of high-cost therapies, hindering progress.

Geopolitical factors, such as trade restrictions, regulatory hurdles, and political instability, can disrupt the global supply chain for necessary raw materials and affect the distribution of therapies. Additionally, ethical concerns and varying regulatory standards across regions may pose challenges to the development and commercialization of personalized treatments. Despite these challenges, the ongoing advancements in biotechnology and the increasing focus on precision medicine are expected to continue driving market growth.

Latest Trends

Surge in Partnerships and Collaborations Driving the Personalized Cell Therapy Market

Increasing partnerships and collaborations are driving significant growth in the personalized cell therapy market. High levels of cooperation between pharmaceutical companies, research institutions, and biotechnology firms are expected to accelerate the development and production of advanced cell therapies. These collaborations provide access to cutting-edge technologies, resources, and expertise, enhancing innovation and expanding market reach.

In June 2023, Vertex Pharmaceuticals Incorporated and Lonza formed a strategic partnership to accelerate the production of fully differentiated insulin-producing islet cell therapies for individuals with type 1 diabetes. This collaboration is focused on the clinical trials of VX-264 and VX-880. As more strategic alliances form in the sector, the market is likely to benefit from enhanced therapeutic offerings, greater efficiency, and increased patient access to groundbreaking cell-based treatments.

Regional Analysis

North America is leading the Personalized Cell Therapy Market

North America dominated the market with the highest revenue share of 41.2% owing to significant advancements in immunotherapy, increased funding for cell therapy research, and a rising demand for targeted treatments. Personalized cell therapies, such as CAR T-cell therapies and stem cell treatments, have demonstrated promising results in treating cancers and autoimmune diseases.

A major milestone in this growth occurred in August 2024 when Adaptimmune Therapeutics PLC received U.S. FDA approval for TECELRA (afamitresgene autoleucel), marking the first engineered cell therapy approved for use in solid tumors, as well as for synovial sarcoma, a rare soft tissue cancer. This approval underscores the increasing recognition of the potential of personalized cell therapies to target specific cancer cells more effectively than traditional treatments.

Additionally, the growing prevalence of cancer and chronic diseases, along with advances in genetic engineering and cell-based technologies, has further fueled the market’s expansion. The increasing focus on personalized medicine, where therapies are tailored to individual patients’ genetic profiles, has positioned North America as a key leader in the development and application of personalized cell therapies.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

Asia Pacific is expected to grow with the fastest CAGR owing to advancements in biotechnology, increasing healthcare investments, and a rising focus on precision medicine. Countries such as China, India, and Japan are expected to see increased demand for cell therapies as healthcare systems modernize and access to cutting-edge treatments improves. The increasing prevalence of cancer, autoimmune diseases, and genetic disorders in the region is likely to accelerate the adoption of personalized cell therapies.

In particular, China’s growing investment in biotechnology and research initiatives, such as stem cell and gene therapy, is expected to play a critical role in expanding the market. The ongoing efforts to improve healthcare infrastructure, coupled with growing collaborations between global pharmaceutical companies and local biotech firms, are anticipated to drive innovation and speed up the availability of personalized therapies. With increasing awareness of the benefits of tailored treatments, the market for personalized cell therapies in Asia Pacific is expected to experience substantial growth in the coming years.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

Key players in the personalized cell therapy market focus on advancing cell engineering technologies, such as CRISPR and CAR-T, to enhance treatment precision and effectiveness. Companies invest in R&D to expand therapeutic applications, including oncology, autoimmune disorders, and regenerative medicine. Collaborations with research institutions and healthcare providers drive innovation and accelerate clinical trial development.

Geographic expansion into regions with growing biotechnology investments and supportive regulatory frameworks strengthens their market reach. Many players also prioritize scalable manufacturing solutions and regulatory compliance to meet increasing demand.

Novartis AG is a leading company in this market, known for its CAR-T cell therapy products like Kymriah, which treat specific blood cancers. The company combines advanced cell engineering with extensive clinical research to develop life-saving therapies. Novartis’ global reach and commitment to innovation position it as a pioneer in the field of personalized medicine.

Top Key Players

• Umoja Biopharma
• QIAGEN
• Precision Biologics
• Janssen Biotech
• Genelex
• Exact Sciences Corporation
• Dako A/S
• Biogen
• Adaptimmune Therapeutics plc
• Abbott

Recent Developments

• In May 2023, Janssen Biotech, part of the Johnson & Johnson, revealed that it had formed a global collaboration as well as license agreement with CBMG (Cellular Biomedicine Group Inc.) to jointly develop and commercialize next-gen chimeric antigen receptor (CAR) T-cell therapies aimed at treating B-cell malignancies.
• In March 2023, Adaptimmune Therapeutics plc and TCR Therapeutics Inc. announced a definitive agreement under which Adaptimmune would merge with TCR in an all-stock deal, forming a leading cell therapy company focused on solid tumors. The merger offers significant advantages for clinical development and product delivery, supported by their complementary technology platforms.
• In January 2024, Umoja Biopharma and AbbVie entered into a strategic partnership to develop multiple in-situ generated CAR-T cell therapy candidates for oncology, leveraging Umoja’s proprietary VivoVec gene delivery platform.

Report Scope